Hit-to-Lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists

https://doi.org/10.1016/j.bmcl.2003.08.034Get rights and content

Abstract

A Hit-to-Lead optimisation programme was carried out on the adamantane high throughput screening hit 1 resulting in the discovery of a number of potent P2X7 antagonists.

A Hit-to-Lead programme was carried out resulting in the discovery of the potent P2X7 antagonists 16 and 31.

  1. Download : Download full-size image

References (14)

  • S.D. Guile et al.

    Prog. Med. Chem.

    (2001)
  • D. Perregaux et al.

    J. Biol. Chem.

    (1994)
  • B. Gu et al.

    Blood

    (1998)
  • W.F. Michne

    Pharm. News

    (1996)
  • R.A. North

    Physiol. Rev.

    (2002)
  • G. Burnstock

    Drug Dev. Res.

    (2001)
  • F. Di Virgilio et al.

    Handbook Exp. Pharmacol.

    (2001)
There are more references available in the full text version of this article.

Cited by (120)

  • Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An Emerging therapeutic tool for treatment of inflammation and neurological disorders

    2022, European Journal of Medicinal Chemistry
    Citation Excerpt :

    These include Suramin, Reactive Blue 2, PPADS and its derivatives [6]. It has been found that most of the known inhibitors for P2X receptor subtypes did not fulfill drug-ability criteria due to the large molecular weight (>700) and high lipophilicity (clogP>6) [7]. Selective antagonists of P2X receptors will find wide range of therapeutic applications for inflammation, pain, osteoporosis, neurodegenerative disorders, spinal cord injury, hypertension, and urinary incontinence.

  • Radioligands targeting purinergic P2X7 receptor

    2020, Bioorganic and Medicinal Chemistry Letters
  • Challenges and Opportunities in Central Nervous System Drug Discovery

    2019, Trends in Chemistry
    Citation Excerpt :

    Amantadine and memantine are extremely simple adamantane derivatives which were among the first pharmaceutical hits in the 1960s, and are used to ameliorate side-effects of Parkinson’s medication levodopa and symptoms of Alzheimer’s, respectively. Since AstraZeneca’s initial research into adamantyl-based compounds as P2X7 antagonists (1; Figure 3) for treatment of chronic inflammatory disease [49], academic research groups have shown the use of trifluoroadamantanes (SMW139) [50], cubanes (2; Figure 3), carboranes (3; Figure 3) [48,49], and bisnoradamantane [51] to antagonize the same receptor [52,53]. In addition to its polycyclic nature, cubane has the added property of being an isostere of benzene [54].

View all citing articles on Scopus
View full text